8UT4 image
Entry Detail
PDB ID:
8UT4
EMDB ID:
Title:
CryoEM structure of A/Michigan/45/2015 H1 in complex with flu HA central stem VH1-18 antibody 09-1B12
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2023-10-30
Release Date:
2024-05-08
Method Details:
Experimental Method:
Resolution:
3.30 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Hemagglutinin HA1 chain
Chain IDs:A, C, E
Chain Length:324
Number of Molecules:3
Biological Source:Influenza A virus
Polymer Type:polypeptide(L)
Description:Hemagglutinin HA2 chain
Chain IDs:B, D, F
Chain Length:250
Number of Molecules:3
Biological Source:Influenza A virus
Polymer Type:polypeptide(L)
Description:09-1B12 LC Fv
Chain IDs:H
Chain Length:109
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:09-1B12 HC Fv
Chain IDs:G (auth: I)
Chain Length:127
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses.
Immunity 57 1141 1159.e11 (2024)
PMID: 38670113 DOI: 10.1016/j.immuni.2024.03.022

Abstact

Broadly neutralizing antibodies (bnAbs) targeting the hemagglutinin (HA) stem of influenza A viruses (IAVs) tend to be effective against either group 1 or group 2 viral diversity. In rarer cases, intergroup protective bnAbs can be generated by human antibody paratopes that accommodate the conserved glycan differences between the group 1 and group 2 stems. We applied germline-engaging nanoparticle immunogens to elicit a class of cross-group bnAbs from physiological precursor frequency within a humanized mouse model. Cross-group protection depended on the presence of the human bnAb precursors within the B cell repertoire, and the vaccine-expanded antibodies enriched for an N55T substitution in the CDRH2 loop, a hallmark of the bnAb class. Structurally, this single mutation introduced a flexible fulcrum to accommodate glycosylation differences and could alone enable cross-group protection. Thus, broad IAV immunity can be expanded from the germline repertoire via minimal antigenic input and an exceptionally simple antibody development pathway.

Legend

Protein

Chemical

Disease

Primary Citation of related structures